Sigmovir Biosystems, Inc.

Sigmovir Biosystems, Inc. is a Maryland-based biotechnology company registered in the System for Award Management (SAM.gov) since October 2010, operating as a for-profit subchapter S corporation located in Potomac. The company specializes in preclinical research focused on infectious diseases, particularly respiratory viruses, with a primary emphasis on developing and utilizing animal models for evaluating vaccines, therapeutics, and diagnostic interventions. Through its scientific expertise, Sigmovir Biosystems provides advanced research services to federal agencies, with a notable concentration on developing and refining animal models, especially the cotton rat model, for studying respiratory syncytial virus (RSV), influenza, and other infectious disease agents.

The company has been awarded multiple federal contracts, primarily from the National Institute of Allergy and Infectious Diseases (NIAID), involving preclinical models of infectious diseases. These contracts have included the provision of reagents for immunologic analysis, collection of metadata from in vivo studies, and development of cotton rat models for evaluating vaccines and therapeutics for respiratory viruses. The contracts have ranged in value from $80,435 to $1,684,845, and have been structured as firm fixed-price and cost-plus-fixed-fee arrangements. None of these contract awards have had specific set-aside designations, indicating open competition. The work has consistently been performed under the NIAID Preclinical Models of Infectious Diseases 2017-2024 master indefinite-delivery/indefinite-quantity contract mechanism.

Sigmovir Biosystems has received federal grants focused on innovative research addressing viral-induced acute lung injury and respiratory disease interventions. The grants, awarded by agencies including NIAID and the National Heart Lung and Blood Institute, have supported projects such as evaluating therapeutic combinations of PPARG agonist and RXR ligand compounds for treating viral-induced lung injury, developing inducible HMGB1 antagonists for viral-induced acute lung injury, and working on virus-specific vaccine development. The grants have involved collaborative research with institutions like the University of Massachusetts Medical School, with project scopes including immunological studies, molecular mechanism investigations, and preclinical model development using cotton rats as research models.

The company holds a significant indefinite delivery contract awarded by NIAID with a ceiling value of $146.3 million, spanning a seven-year ordering period. This single-award contract aims to provide comprehensive capabilities for developing and employing animal and animal replacement models of infectious diseases. The contract supports NIAID's mission by enabling the development of small animal, non-human primate, and non-traditional animal models for evaluating countermeasures against priority infectious diseases. Through this contract, Sigmovir Biosystems will support the generation and distribution of specialized reagents, facilitate screening and product evaluation, and contribute to potential clinical evaluation strategies for infectious disease interventions.